Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on May 17, 2021. The filing serves to announce the company's financial results for the three-month period ended March 31, 2021. The registrant is incorporated in California and lists its common stock on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results have been issued via a press release, which is attached as Exhibit 99.1 and incorporated by reference. Consequently, no quantitative financial metrics can be extracted directly from this 8-K text.
Material Changes
The filing does not contain a comparative analysis or specific details regarding material changes versus the prior comparable period. It solely references the attached press release for the full disclosure of operational results.
Guidance, Outlook, and Risks
The filing includes a standard forward-looking statements disclaimer. It warns that statements containing words such as "may," "will," "believes," or "expects" are not historical facts and are subject to risks and uncertainties. The company directs investors to the "Risk Factors" section of its Annual Report on Form 10-K for additional factors that could cause actual results to differ materially from anticipated results. OncoCyte explicitly disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release dated May 17, 2021) for specific revenue, net loss, and cash position figures for the quarter ended March 31, 2021.
- Consult the most recent Form 10-K to understand the specific risk factors referenced in the forward-looking statements.
- Verify the company's cash runway and burn rate, as these are critical for a biotechnology firm but are not detailed in this summary filing.
- Check for any subsequent filings that may update the forward-looking statements or provide interim financial data.